New rules may dampen Chinese investment in biotech
U.S. biotech is funded increasingly by Chinese investors. But the Trump administration issued a new set of rules last month that call for additional scrutiny of some foreign investments — leading many in biotech to wonder whether this might slow the flow of Chinese dollars into the sector. What’s unclear, however, is how these new regulations will be enforced.
STAT’s Rebecca Robbins and Ike Swetlitz took a deeper look into the kinds of investments, companies, and products that are likely to be impacted by these rules — and what the new rules might look like from abroad.
STAT’s Rebecca Robbins and Ike Swetlitz took a deeper look into the kinds of investments, companies, and products that are likely to be impacted by these rules — and what the new rules might look like from abroad.
.png)
No hay comentarios:
Publicar un comentario